Inhibitory effect of epirubcin hydrochloride co-treated with oxaliplatin in the apoptosis of HepG2 cells

Abstract

Abstract: AIM: To investigate the inhibitory effect of epirubcin hydrochloride in combination use with oxaliplatin (L-OHP) on the hepatocellular carcinoma cells HepG2.METHODS: The inhibitory effect of epirubicin hydrochloride together with L-OHP on the growth of human hepatic carcinoma cell line HepG2 in vitro was evaluated by MTT assay. The apoptosis of nucleus was detected by Hoechst33258 staining. The degradation of DNA was evaluated by DNA ladder.RESULTS: Oxaliplatin and epirubicin hydrochloride both inhibited the proliferation of HepG2 cells, it presented addictive inhibition effect when two medicine combined (q value was in 0.85-1.15).CONCLUSION: Oxaliplatin and epirubicin hydrochloride both inhibited the proliferation of HepG2 cells and promoted apoptosis, combination of these medicine presented addictive inhibition effect, however, the mechanism was unclear.

Key words: Hepatocellular carcinoma, Oxaliplatin, Epirubicin hydrochloride, Apoptosis

CLC Number:

R965.2

WANG Ning, ZHANG Yang-de, LIAO Ming-mei, ZHAO Jin-feng, CHEN Wei. Inhibitory effect of epirubcin hydrochloride co-treated with oxaliplatin in the apoptosis of HepG2 cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(5): 490-494.

References

[1] 储玉山,朱小庆,张玉宇,等. 索拉非尼联合奥沙利铂对肝癌HepG2细胞的抑制作用[J]. 介入放射学杂志, 2011, 20(10): 810-814.
[2] 熊奇如,夏俊,李立祥,等. 脂氧化酶抑制剂对肝癌细胞株HepG2增殖及MEK/ERK信号通路的影响[J]. 中国临床药理学与治疗学, 2012, 17(1): 1-5.
[3] 许小兵, 张晓华, 杨妙芳, 等. PTPeta介导生长抑素对SMMC7721生长抑制作用的实验研究[J]. 中国临床药理学与治疗学, 2011, 16(11): 1222-1226.
[4] Bioge V, Raoul JL, Pignon JP, et al. Multicentre phaseII trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial [J]. Br J Cancer, 2007, 97(7): 862-867.
[5] Zhao S, Cai J, Bian H, et al. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin [J]. Cancer Invest, 2009, 27(6): 636-640.
[6] 刘亚贤,赵宏然,赵海. 奥沙利铂联合表柔比星在原发肝癌介入治疗的疗效观察[J]. 齐齐哈尔医学院学报, 2012, 33(1): 35-36.
[7] Saimura M, Anan K, Mitsuyama S. A multicenter study of epirubicin-docetaxe(ET) as primary chemotherapy for patients with inflammatory breast cancer (IBC) [J]. Cancer Chemoth, 2012, 39(7): 1075-1079.
[8] Reni M, Balzano G, Aprile G. Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: A randomized phase II trial [J]. Ann Surg Oncol, 2012, 19(7): 2256-2263.
[9] Seki A, Hori S. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma[J]. Cadd Interv Radiol, 2012, 35(3): 555-562.
[10] 李海涛,解皓. 奥沙利铂联合表柔比星、氟尿嘧啶在中晚期原发性肝癌介入治疗中的疗效观察[J]. 临床合理用药, 2012, 5(10A): 8-9.
[11] Tang H, Yuan JL, Liu M, et al. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC307/L-OHP [J]. Prec Rep, 2007, 18(6): 633-639.
[12] Inoue K, Narukawa M, Takeuchi M. Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials [J]. Lung, 2012, 190(4): 355-364.

[1]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[2]	YANG Xiaojia, JIANG Meng, WU Min, ZHANG Yili, LV Lan, WU Yuanfen, WANG Xinyu, LIU Liquan. Improvement effect of crocin on cognitive impairment of Alzheimer's disease rats through DKK3 regulation of GSK-3 β/β-Catenin pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 489-497.
[3]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[4]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[5]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[6]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[7]	WU Xianchuang, LIU Yuxin, NIU Yuji, HE Jinjin, QIAO Hui, ZHANG Leilei. Mechanism of DCLK1 transcriptional regulation in HCC [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1241-1246.
[8]	ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun. PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
[9]	HUA Haiyan, YAN Jie, QIN Yufen. Experimental study of schisandrin B attenuates acute myocardial ischemia injury in rats by inhibiting cardiomyocyte apoptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 848-856.
[10]	LI Xueheng, LI Long. Research progress on the relationship between melatonin and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 715-720.
[11]	CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177.
[12]	YANG Liu, LUO Ailin, LI Shiyong. Advance of general anesthetics-induced developing brain injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1381-1390.
[13]	TAN Fenglang, REN Hongli, WANG Hongfei. Effect of Phellodendri amurense extract on hippocampal nerve cells induced by Aβ_1-42 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1213-1220.
[14]	PAN Rongrong, ZHI Yinghao, JIN Yongxi, ZHOU Xiahui. Influences of theaflavins on neuronal apoptosis and blood-brain barrier in rats with cerebral hemorrhage by regulating CaMKK2/AMPK signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1240-1246.
[15]	LI Ying, YAO Wei, WANG Meng, YU Zhihong, GONG Yuanqi, LAN Haibing, QI Xiefei. Experimental study of irisin alleviates house dust mite-induced airway epithelial cells inflammation and apoptosis via the NF-κB and JNK signaling pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1106-1112.